Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer
作者： S. Jones , C. Vogel , A. Arkhipov , L. Fehrenbacher , P. Eisenberg
DOI: 10.1200/JCO.1999.17.11.3418
关键词:
摘要: … Most patients with CR/PR (83%; 10 of 12 patients) and SD ≥ 24 weeks (80%; 12 of 15 patients) had improved or stable tumor-related signs and symptoms. Mean levels of circulating …
elsevier.com
sci-hub.se 参考文章(15)
A Buzdar, W Jonat, A Howell, S E Jones, C Blomqvist, C L Vogel, W Eiermann, J M Wolter, M Azab, A Webster, P V Plourde, Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology. ,vol. 14, pp. 2000- 2011 ,(1996) , 10.1200/JCO.1996.14.7.2000
G Ornati, J Paolini, P E Lonning, G Piscitelli, E Di Salle, S Kvinnsland, D C Johannessen, M G Zurlo, T Engan, Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research. ,vol. 3, pp. 1101- 1108 ,(1997)
P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, H A Chaudri, U Hornberger, P F Trunet, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology. ,vol. 16, pp. 453- 461 ,(1998) , 10.1200/JCO.1998.16.2.453
P.E. Lønning, S. Kvinnsland, Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer Drugs. ,vol. 35, pp. 685- 710 ,(1988) , 10.2165/00003495-198835060-00005
E. Di Salle, G. Briatico, D. Giudici, G. Ornati, T. Zaccheo, F. Buzzetti, M. Nesi, A. Panzeri, Novel aromatase and 5α-reductase inhibitors The Journal of Steroid Biochemistry and Molecular Biology. ,vol. 49, pp. 289- 294 ,(1994) , 10.1016/0960-0760(94)90270-4
D. Giudici, G. Ornati, G. Briatico, F. Buzzetti, P. Lombardi, E. di Salle, 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A New Irreversible Aromatase Inhibitor Journal of Steroid Biochemistry. ,vol. 30, pp. 391- 394 ,(1988) , 10.1016/0022-4731(88)90129-X
James N. Ingle, Patricia A. Johnson, Vera J. Suman, James B. Gerstner, James A. Mailliard, John K. Camoriano, Dean H. Gesme, Charles L. Loprinzi, Alan K. Hatfield, Lynn C. Hartmann, A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. ,vol. 80, pp. 218- 224 ,(1997) , 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P
Nuhad K. Ibrahim, Aman U. Buzdar, Aromatase inhibitors: Current status American Journal of Clinical Oncology. ,vol. 18, pp. 407- 417 ,(1995) , 10.1097/00000421-199510000-00010
E. Salle, D. Giudici, G. Briatico, G. Ornati, Novel irreversible aromatase inhibitors. Annals of the New York Academy of Sciences. ,vol. 595, pp. 357- 367 ,(1990) , 10.1111/J.1749-6632.1990.TB34309.X
J. M. GRODIN, P. K. SIITERI, P. C. MACDONALD, Source of Estrogen Production in Postmenopausal Women The Journal of Clinical Endocrinology and Metabolism. ,vol. 36, pp. 207- 214 ,(1973) , 10.1210/JCEM-36-2-207